Get the Stockscreener App
16.86
0.48%
0.08
Telix Pharmaceuticals Ltd Adr stock is traded at $16.86, with a volume of 17,326.
It is up +0.48% in the last 24 hours and up +6.57% over the past month.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
See More
Previous Close:
$16.78
Open:
$18
24h Volume:
17,326
Relative Volume:
1.84
Market Cap:
$5.64B
Revenue:
$417.75M
Net Income/Loss:
$32.27M
P/E Ratio:
172.92
EPS:
0.0975
Net Cash Flow:
-
1W Performance:
+8.63%
1M Performance:
+6.57%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$16.77
$18.00
1-Week Range:
$15.54
$18.04
52-Week Range:
$14.01
$18.04
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Name
Telix Pharmaceuticals Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare TLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
16.86 | 5.64B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Initiated | UBS | Buy |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Latest News
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Health Check: ASX sleep company emerges from slumber with a revenue and earnings upgrade - Stockhead
UBS bullish on Telix stock—Illuccix growth & therapeutic expansion fuel upside - Investing.com
Telix Pharmaceuticals Debuts on Nasdaq Global Select Market Under TLX Symbol - StockTitan
Telix spins off radiopharma unit to form Rhine Pharma | Pharmaceutical | The Pharmaletter - The Pharma Letter
Guess which top 100 ASX stock is venturing off to the Nasdaq - The Motley Fool Australia
Telix Files Form 20-F Registration Statement for Nasdaq ADS - Yahoo Finance
Up 66% in FY24, will Telix Pharmaceuticals shares continue? - The Motley Fool Australia
TLX ASX: Telix pulls $300m Nasdaq IPO as investors demand deep discount - The Australian Financial Review
Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma
Australia's Telix Pharmaceuticals jumps on potential US listing - Reuters
Queen's University Leads Irish Trial of New Prostate Cancer Treatment - Imaging Technology News
Telix Pharmaceuticals Ltd Adr Stock (TLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):